Aurobindo Pharma Limited — Updates, 26-05-2025: Press Release

Aurobindo Pharma has announced a board meeting on to approve the financial results for the quarter and half-year. Q4 revenue rose 10.6% YoY to INR 8,382 Cr, led by strong US (+13.5%) and Europe (+17.2%) formulations. Growth Markets declined 7.8%, while ARV and API segments grew 29.4% and 5.0%, respectively. EBITDA before R&D was INR 2,202 Cr (26.3% margin) with net profit at INR 903 Cr. The company strengthened its pipeline by filing 9 new ANDAs and receiving final approval for 5.